AQST Quick Ratio | Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Aquestive Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 5.98, a 128.62% increase year-over-year.
Aquestive Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 3.49, a 7.06% decline year-over-year.
Aquestive Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 2.55, a 32.89% decline year-over-year.
Aquestive Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 5.05, a 1.83% decline year-over-year.
Aquestive Therapeutics, Inc. quick ratio for fiscal 2025 was 2.55, a 32.89% decline from fiscal 2024.
Aquestive Therapeutics, Inc. quick ratio for fiscal 2024 was 3.79, a 190.86% increase from fiscal 2023.
Aquestive Therapeutics, Inc. quick ratio for fiscal 2023 was 1.3, a 88.98% increase from fiscal 2022.
Aquestive Therapeutics, Inc. quick ratio for fiscal 2022 was 0.69, a 45.92% decline from fiscal 2021.

Available history: 2017-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	5.98	$98.49M	$16.48M
2026-03-31	3.49	$110.73M	$31.75M
2025-12-31	2.55	$121.17M	$47.61M
2025-09-30	5.05	$129.06M	$25.57M
2025-06-30	2.61	$60.54M	$23.16M
2025-03-31	3.75	$68.66M	$18.3M
2024-12-31	3.79	$71.55M	$18.87M
2024-09-30	5.14	$77.89M	$15.15M
2024-06-30	6.47	$89.87M	$13.9M
2024-03-31	5.27	$95.2M	$18.06M
2023-12-31	1.3	$23.87M	$18.31M
2023-09-30	1.04	$24.92M	$24.06M
2023-06-30	0.58	$22.44M	$38.65M
2023-03-31	0.67	$26.88M	$40.38M
2022-12-31	0.69	$27.27M	$39.53M
2022-09-30	0.51	$18.65M	$36.56M
2022-06-30	0.6	$17.7M	$29.64M
2022-03-31	0.61	$14.74M	$24.18M
2021-12-31	1.28	$28.02M	$21.96M
2021-09-30	1.24	$31.16M	$25.04M
2021-06-30	1.49	$34.23M	$23.04M
2021-03-31	1.37	$27.5M	$20.05M
2020-12-31	1.51	$31.81M	$21.1M
2020-09-30	0.93	$17.06M	$18.37M
2020-06-30	1.71	$25.42M	$14.88M
2020-03-31	2.31	$35.52M	$15.36M
2019-12-31	2.66	$49.33M	$18.56M
2019-09-30	1.04	$20.91M	$20.05M
2019-06-30	0.9	$22.17M	$24.63M
2019-03-31	1.35	$39.93M	$29.64M
2018-12-31	2.04	$67.08M	$32.95M
2018-09-30	3.35	$71.43M	$21.33M
2018-06-30	0.74	$17.27M	$23.47M
2017-12-31	1.53	$23.56M	$15.35M

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	2.55	$121.17M	$47.61M
2024-12-31	3.79	$71.55M	$18.87M
2023-12-31	1.3	$23.87M	$18.31M
2022-12-31	0.69	$27.27M	$39.53M
2021-12-31	1.28	$28.02M	$21.96M
2020-12-31	1.51	$31.81M	$21.1M
2019-12-31	2.66	$49.33M	$18.56M
2018-12-31	2.04	$67.08M	$32.95M
2017-12-31	1.53	$23.56M	$15.35M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
CorMedix Inc. (CRMD)	United States	$0.605B	3.25
IMPACT BIOMEDICAL INC. (IBO)	United States	$0.611B	66.47
CytomX Therapeutics, Inc. (CTMX)	United States	$0.598B	-10.25
Monopar Therapeutics (MNPR)	United States	$0.598B	-34.82
Altimmune, Inc. (ALT)	United States	$0.593B	-6.43
Neurogene Inc. (NGNE)		$0.625B	-4.46
Shattuck Labs, Inc. (STTK)	United States	$0.634B	-13.30
Phathom Pharmaceuticals, Inc. (PHAT)	United States	$0.572B	-8.76
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
ZEVRA THERAPEUTICS, INC. (ZVRA)	United States	$0.668B	14.61